Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer

16 de novembro de 2026 atualizado por: Lee, Soo Hyeon, Korea University Anam Hospital

A Phase 2, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Erlotinib in Patients With EGFR-Amplified Metastatic Colorectal Cancer Who Have Failed or Are Not Eligible for Oxaliplatin- and Irinotecan-Based Chemotherapy

This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.

Visão geral do estudo

Descrição detalhada

This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.

Tipo de estudo

Intervencional

Inscrição (Estimado)

39

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Histologically or cytologically proven metastatic/recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).

  2. EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.

  3. Measurable disease per RECIST version 1.1 (measurable lesions are not mandatory for study entry).

  4. Age ≥ 19 years.

  5. ECOG performance status 0-2.

  6. Adequate bone marrow and organ function:

    • Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
    • Hemoglobin (Hgb) ≥ 9.0 g/dL
    • Platelet count ≥ 75 x 10^9/L
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 30 mL/min
    • Total bilirubin ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
    • AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
  7. Adequate cardiac function: QTc ≤ 480 msec (if QTc > 480 msec, average QTc < 480 msec in triplicate measurements).

  8. Ability to swallow oral medication.

  9. Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of childbearing potential.

  10. Agreement to use appropriate contraception methods as outlined in the protocol.

  11. Life expectancy ≥ 3 months.

  12. Signed and dated informed consent prior to any study-related procedures.

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
  3. Known hypersensitivity to the study drug components.
  4. Cytotoxic chemotherapy within 14 days, investigational drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
  5. Uncontrolled severe infection.
  6. Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging QTc.
  7. Active central nervous system (CNS) metastases (unless radiologically stable, asymptomatic, and off steroids for at least 4 weeks; leptomeningeal disease is excluded).
  8. History of another primary malignancy (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
  9. Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
  10. Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
  11. Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
  12. Thrombotic or thromboembolic events within 6 months.
  13. History or evidence of bleeding disorders.
  14. Therapeutic use of maximum dose anticoagulants.
  15. Unhealed wounds, acute ulcers, or bone fractures.
  16. Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
  17. Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
  18. History or pathological findings of major GI surgery that may impair oral absorption.
  19. Evidence of active infection including Hepatitis B, Hepatitis C, or HIV (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
  20. Conditions or diseases deemed by the investigator to contraindicate study participation.
  21. Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Bevacizumab plus Erlotinib

Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg.

Administered at 7.5 mg/kg intravenously every 3 weeks.

Outros nomes:
  • Onbevzi

Administered at 150 mg orally daily.

Outros nomes:
  • Eltinib

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-Free Survival (PFS)
Prazo: From the first dose of study treatment until disease progression or death, assessed up to 12 months

PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause.

From the first dose of study treatment until disease progression or death, assessed up to 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Objective Response Rate (ORR)
Prazo: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1.

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Overall Survival (OS)
Prazo: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up

OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date

From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
Disease Control Rate (DCR)
Prazo: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Duration of Response (DOR)
Prazo: From initial response until documented disease progression, assessed up to approximately 12 months

Calculated from the time initial response (CR or PR) is documented until the date of progressive disease

From initial response until documented disease progression, assessed up to approximately 12 months
Time to Response (TTR)
Prazo: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months

Calculated from the first dose of study treatment to the date of initial response (CR or PR)

From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
Safety and Tolerability
Prazo: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months

Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0

From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
Quality of Life (QoL) EORTC QLQ-C30
Prazo: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
Quality of Life (QoL) CR26
Prazo: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

4 de janeiro de 2027

Conclusão Primária (Estimado)

31 de janeiro de 2028

Conclusão do estudo (Estimado)

31 de janeiro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.

Prazo de Compartilhamento de IPD

Beginning 3 months and ending 5 years following article publication.

Critérios de acesso de compartilhamento IPD

De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever